Summary: The drug Canakinumab reduced heart attacks by 25% and cancer by 50% by reducing chronic inflammation, according to the authors of the recent CANTOS trial. [This report was originally published on LongevityFacts on Aug 27, 2017, and has been updated. Author: Brady Hartman] In late August, researchers announced that they had found a breakthrough drug which reduces heart attack risk by one-fourth … Continue reading New Breakthrough Drug Canakinumab Slashes Heart Attack and Cancer in Clinical Trial